ICTM logo
MRC CTU Testis Collaborators Meeting, 12th May 2008

25 March 2008

The MRC CTU are holding a day meeting at Institute of Physics, 76 Portland Place, London, which will cover the Unit's work in testis cancer. The meeting is open to all research staff who have worked on or are working on MRC testis trials.

The day will be split into 3 sections:

TE23 Investigators meeting chaired by Dr Robert Huddart, TE23 Chief Investigator (am)
The trial has recently undergone a protocol amendment to include additional information on the management of patients and a change to information given to patients and this will be discussed during the course of the morning. Other information presented will include an update on recruitment, review of baseline characteristics of patients in the trial, data return and compliance.

Updated results from MRC testis trials (TE10, TE18 & TE19) presented by Dr Ben Mead and Prof Tim Oliver plus update on the current NCRI testis portfolio (lunch)
Over the last year the CTU have been updating the follow-up data on patients who participated in three MRC stage I seminoma studies with the intent to submit an updated analyses to ASCO (American Society of Clinical Oncology). Two abstracts were submitted to ASCO and have been accepted for their annual meeting which takes place from 30th May to 3rd June 2008 in Chicago, Illinois, USA. The first abstract, which has been accepted for the plenary session, contains data from the TE19 trial on long-term relapse-free rates, survival and 2nd germ cell and non-germ cell cancers plus some exploratory analyses relating to the carboplatin arm. The 2nd abstract focused on late relapses and the means of detection of relapse in stage I seminoma generally, brief updates on the long-term results of TE10, TE18 and TE19 and further data which has recently been collected on the means by which relapse was first detected in TE19.

TRISST (TE24) Launch meeting chaired by Dr Johnathan Joffe, TE24 Chief Investigator (pm)
The purpose of TRISST is to assess whether a reduced computed tomography (CT) schedule or Magnetic Resonance Imaging (MRI) could be used as a safe and effective alternative to standard CT-based surveillance in the management of stage I seminoma testis patients in a randomised phase III trial. This is an important trial and the comparison of CT and MRI in this setting has generated a great deal of interest. We hope to recruit 660 patients over 5 years. Three centres have already been accredited to enter patients into the trial; St James University Hospital, Leeds; James Cook University Hospital, Middlesbrough; and Christie Hospital, Manchester. Further centres are applying to take part in the trial and it is anticipated that 30-40 centres across the UK will participate in total. Later in 2008 it is hoped that collaborations with international groups will enable other countries, such as Canada, to participate in TRISST.